Selective intracellular delivery of perfluorocarbon nanodroplets for cytotoxicity threshold reduction on ultrasound-induced vaporization.
Cell Line, Tumor
Cell Survival
/ drug effects
Combined Modality Therapy
/ methods
Drug Delivery Systems
/ methods
Drug Screening Assays, Antitumor
Fluorocarbons
/ administration & dosage
Humans
Nanomedicine
/ methods
Nanoparticles
/ administration & dosage
Neoplasms
/ drug therapy
Particle Size
Ultrasonic Waves
Volatilization
/ radiation effects
acoustic droplet vaporization
intracellular vaporization
perfluorocarbon
phase‐change nanodroplets
stimuli‐responsive materials
ultrasound
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
07
09
2018
revised:
21
01
2019
accepted:
25
01
2019
entrez:
29
7
2020
pubmed:
29
7
2020
medline:
5
10
2021
Statut:
ppublish
Résumé
Phase-change nanodroplets (PCNDs), which are liquid perfluorocarbon nanoparticles, have garnered much attention as ultrasound-responsive nanomedicines. The vaporization phenomenon has been employed to treat tumors mechanically. However, the ultrasound pressure applied to induce vaporization must be low to avoid damage to nontarget tissues. Here, we report that the pressure threshold for vaporization to induce cytotoxicity can be significantly reduced by selective intracellular delivery of PCNDs into targeted tumors. In vitro experiments revealed that selective intracellular delivery of PCNDs induced PCND aggregation specifically inside the targeted cells. This close-packed configuration decreased the pressure threshold for vaporization to induce cytotoxicity. Moreover, following ultrasound exposure, significant decrease was observed in the viability of cells that incorporated PCNDs (35%) but not in the viability of cells that did not incorporate PCNDs (88%). Intracellular delivery of PCNDs reduced ultrasound pressure applied for vaporization to induce cytotoxicity. Confocal laser scanning microscopy and flow cytometry revealed that prolonged PCND-cell incubation increased PCND uptake and aggregation. This aggregation effect might have contributed to the cytotoxicity threshold reduction effect.
Sections du résumé
BACKGROUND
Phase-change nanodroplets (PCNDs), which are liquid perfluorocarbon nanoparticles, have garnered much attention as ultrasound-responsive nanomedicines. The vaporization phenomenon has been employed to treat tumors mechanically. However, the ultrasound pressure applied to induce vaporization must be low to avoid damage to nontarget tissues.
AIMS
Here, we report that the pressure threshold for vaporization to induce cytotoxicity can be significantly reduced by selective intracellular delivery of PCNDs into targeted tumors.
METHODS AND RESULTS
In vitro experiments revealed that selective intracellular delivery of PCNDs induced PCND aggregation specifically inside the targeted cells. This close-packed configuration decreased the pressure threshold for vaporization to induce cytotoxicity. Moreover, following ultrasound exposure, significant decrease was observed in the viability of cells that incorporated PCNDs (35%) but not in the viability of cells that did not incorporate PCNDs (88%).
CONCLUSIONS
Intracellular delivery of PCNDs reduced ultrasound pressure applied for vaporization to induce cytotoxicity. Confocal laser scanning microscopy and flow cytometry revealed that prolonged PCND-cell incubation increased PCND uptake and aggregation. This aggregation effect might have contributed to the cytotoxicity threshold reduction effect.
Identifiants
pubmed: 32721118
doi: 10.1002/cnr2.1165
pmc: PMC7941471
doi:
Substances chimiques
Fluorocarbons
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1165Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Ultrasound Med Biol. 2003 Sep;29(9):1359-65
pubmed: 14553814
Cancer Res. 2013 Apr 15;73(8):2412-7
pubmed: 23423979
Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):1697-702
pubmed: 24449879
Cancer Rep (Hoboken). 2019 Aug;2(4):e1165
pubmed: 32721118
Nat Mater. 2013 Nov;12(11):991-1003
pubmed: 24150417
Sci Rep. 2017 Mar 23;7:44077
pubmed: 28333127
Langmuir. 2011 Sep 6;27(17):10412-20
pubmed: 21744860
Theranostics. 2013 Oct 20;3(11):851-64
pubmed: 24312155
Ultrasound Med Biol. 2013 Mar;39(3):475-89
pubmed: 23312960
Theranostics. 2017 Apr 3;7(6):1477-1488
pubmed: 28529631
Biomaterials. 2015;53:699-708
pubmed: 25890765
Ultrasound Med Biol. 2000 Sep;26(7):1177-89
pubmed: 11053753
Ultrasound Med Biol. 2011 Sep;37(9):1518-30
pubmed: 21775049
Ultrasound Med Biol. 2012 Oct;38(10):1799-810
pubmed: 22920544
Biomaterials. 2013 Feb;34(7):1852-61
pubmed: 23219326
Ultrasound Med Biol. 2011 Nov;37(11):1952-7
pubmed: 21963036
Biochem Biophys Res Commun. 2013 Nov 29;441(4):1011-7
pubmed: 24239549
J Biol Chem. 2016 Jan 29;291(5):2319-30
pubmed: 26627827
Adv Mater. 2015 Oct 7;27(37):5484-92
pubmed: 26265592
ACS Biomater Sci Eng. 2015 Feb 9;1(2):64-78
pubmed: 25984571
Biomaterials. 2012 Apr;33(11):3262-9
pubmed: 22289265
Nat Med. 2011 Nov 06;17(12):1685-91
pubmed: 22057348
J Acoust Soc Am. 2013 Aug;134(2):1610-21
pubmed: 23927201
Adv Healthc Mater. 2015 Aug 26;4(12):1790-5
pubmed: 26084414
Appl Phys Lett. 2014 Feb 10;104(6):063703
pubmed: 24711671
J Control Release. 2011 Jul 15;153(1):4-15
pubmed: 21277919
Acta Biomater. 2017 Feb;49:472-485
pubmed: 27836803
Ultrasound Med Biol. 2018 May;44(5):1031-1043
pubmed: 29525455
Adv Mater. 2013 Aug 14;25(30):4123-30
pubmed: 23788403
Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):598-607
pubmed: 18045727
Ultrasonics. 2016 Jul;69:97-105
pubmed: 27082763
Adv Drug Deliv Rev. 2013 Jan;65(1):71-9
pubmed: 23088862
Nat Commun. 2012 Jan 10;3:618
pubmed: 22233628
Biomaterials. 2012 Feb;33(6):1939-47
pubmed: 22142768
J Med Ultrason (2001). 2015 Oct;42(4):457-66
pubmed: 26576970